Deferasirox, an iron chelator, impacts myeloid differentiation by modulating NF-kB activity via mitochondrial ROS
Ontology highlight
ABSTRACT: Deferasirox (DFX) can improve erythropoiesis in patients with MDS. We sought to test how these changes occur and whether myelopoiesis broadly is affected by analyzing neutrophils and neutrophil precursors treated with DFX.
ORGANISM(S): Homo sapiens
PROVIDER: GSE274956 | GEO | 2024/09/27
REPOSITORIES: GEO
ACCESS DATA